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TheNLRP3 inflammasome is a central regulator of inflamma-
tion in many common diseases, including atherosclerosis and
type 2 diabetes, driving the production of pro-inflammatory
mediators such as IL-1 and IL-18. Due to its function as an
inflammatory gatekeeper, expression and activation of NLRP3
need to be tightly regulated. In this study, we highlight novel
post-transcriptional mechanisms that can modulate NLRP3
expression. We have identified the RNA-binding protein Tris-
tetraprolin (TTP) as a negative regulator of NLRP3 in human
macrophages. TTP targets AU-rich elements in the NLRP3
3-untranslated region (UTR) and represses NLRP3 expression.
Knocking down TTP in primary macrophages leads to an
increased induction of NLRP3 by LPS, which is also accompa-
nied by increased Caspase-1 and IL-1 cleavage upon NLRP3,
but not AIM2 or NLRC4 inflammasome activation. Further-
more, we found that human NLRP3 can be alternatively poly-
adenylated, producing a short 3-UTR isoform that excludes
regulatory elements, including the TTP- andmiRNA-223-bind-
ing sites. Because TTP also represses IL-1 expression, it is a
dual inhibitor of the IL-1 system, regulating expression of the
cytokine and the upstream controller NLRP3.
TheNLRP3 inflammasome has emerged as a potent driver of
many common inflammatory diseases, due to its ability to
induce production of the pro-inflammatory cytokines IL-1
and IL-18, as well as pyroptosis, a pro-inflammatory type of cell
death (reviewed in Ref. 1). After a “licensing” signal down-
stream of Toll-like receptor activation, which primes the sys-
tem transcriptionally (2) and post-translationally (3), NLRP3
can be activated by a vast number of structurally diverse stimuli,
from bacterial toxins to extracellular ATP and protein or crys-
talline aggregates (1). Even though themolecularmechanismof
NLRP3 activation is still not fully understood, potassium efflux
appears to be a common requirement and ultimately leads to
the interaction of NLRP3 with the adaptor protein ASC and
Pro-Caspase-1, which aggregate to form the inflammasome (4).
Once initiated, the inflammasomeprovides a platform for auto-
activation of Caspase-1, which in turn cleaves downstream
effectors. Most notably, Caspase-1 processes the inactive pre-
cursors of IL-1 and IL-18 into the active cytokines (5) and
cleaves Gasdermin D to initiate pyroptotic cell death (6, 7). In
the broadest sense, NLRP3 activators are signs of “disturbed
homeostasis,” for example, as the result of infection or tissue
damage. Of particular interest is that the deposition of NLRP3
stimuli is a feature of many common inflammatory diseases,
including type 2 diabetes, atherosclerosis, gout, and Alzhei-
mer’s disease (8–11). Many studies over the last decade have
demonstrated that NLRP3 activation is functionally relevant in
disease models, because pharmacological or genetic inhibition
of NLRP3 activation is protective (12). Due to its central role as
an inflammatory gatekeeper, NLRP3 expression and activation
are tightly regulated. For example, NFB can drive NLRP3
transcription downstream of Toll-like receptor or cytokine
activation (2, 13). Furthermore, the NLRP3 protein can be
post-translationally modified in a number of ways, including
ubiquitination, phosphorylation, ADP-ribosylation, and nitro-
sylation (14). Many modifications inhibit inflammasome for-
mation and need to be removed in the “priming” step to allow
for efficient activation (3). Finally, we and others have demon-
strated thatmiRNA-223 can repressNLRP3 expression inmye-
loid cells (15, 16).
Even though post-transcriptional mechanisms are central to
the regulation of innate immune signaling (17), apart frommiR-
223,3 very little is known about post-transcriptional regulation
ofNLRP3. In this study, we provide the first detailed character-
ization of the 3-untranslated region (UTR) of the NLRP3 gene
in mouse and human. We identify two 3-UTR isoforms in
human (a long and a short) and one inmouse, corresponding to
the long human isoform. The long human isoform has several
AU-rich elements (AREs). We identify the RNA-binding pro-
tein Tristetraprolin (TTP, encoded by ZFP36) as an inducible
repressor of the long isoformofNLRP3 in humanmacrophages,
inhibition of which likely contributes to inflammasome prim-
ing. Because TTP also targets expression of the downstream
effector IL-1, it appears to be particularly important for con-
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trolling the IL-1 system, regulating both the cytokine and its
key controller, NLRP3.
Results
The NLRP3 3-UTR is alternatively polyadenylated and
contains a repressive AU-rich element
During detailed analysis of the human NLRP3 sequence, we
noticed that expressed sequence tags (ESTs) indicated alterna-
tive 3-ends of transcripts, even though only one 3-UTR is
annotated in RefSeq (Fig. 1a). The alternative isoform that is
suggested by ESTs comprises almost exactly the first half of the
full-length sequence. Polyadenylation sites are located at the
3-end of both isoforms, suggesting that they could arise from
alternative polyadenylation. To verify expression of the iso-
forms experimentally, we analyzed expression of NLRP3 in
monocytes and macrophages by 3-RACE. This successfully
amplified two isoforms of the expected lengths,600 bp for the
long and 300 bp for the short isoform (Fig. 1b). We also esti-
mated the relative expression levels of the 3-UTR isoforms
from different RNA sequencing datasets. The average signal
intensity of the short and long 3-UTR isoform in samples gen-
erated by the ENCODE consortium, Roadmap Epigenomics
project, or GTEx project revealed a big variability of their rela-
tive expression among cell types and tissues (Fig. 1, c–e, and
supplemental Fig. S1). In most samples, the short isoform was
more abundant than the long isoform. However, the ratio of
short to long ranged from below 1 to 20. In particular mono-
cytes appear to express predominantly the short 3-UTR iso-
form. Higher expression of the short isoform in monocytes
could also be confirmed by 3-RACE and qPCR (Fig. 1, b and f).
In contrast, macrophages expressed the isoforms at similar lev-
els (Fig. 1, b and f). In terms ofGCcontent and conservation, the
two halves of the humanNLRP3 3-UTR are very different. The
more conserved distal half of the 3-UTR, which is excluded
from the short isoform, has amuch lowerGCcontent (25 versus
55%) and also contains AREs (Fig. 1a and supplemental Fig. S2,
a and d). In particular, a main ARE consisting of three overlap-
pingAUUUApentamers is present in this region, in close prox-
imity to the target site formiR-223 (15) (supplemental Fig. S2d).
Interestingly, these features are only partially conserved in the
mouse gene. For a start, even though the proximal polyadenyl-
ation site is conserved in many species, it is mutated in the
murine sequence (AAUAAA3 AAGAAA) (supplemental Fig.
S2b). Although the mutated sequence has also been identified
as an active polyadenylation site (18), it is a lot weaker than the
canonical sequence (19). In agreement with a weak proximal
polyadenylation site, we could only detect one isoform of the
murine Nlrp3 3-UTR by 3-RACE (supplemental Fig. S2c).
Similarly, the main human ARE is conserved in many species,
but not in the mouse (supplemental Fig. S2d). However, the
mouse 3-UTR also contains AREs and the human and mouse
full-length 3-UTR indeed show a similar enrichment of AREs
as quantified by the AREScore algorithm (20) (supplemental
Fig. S2a). To test if the isoforms are differentially regulated, we
generated a range of luciferase reporters containing the two
isoforms or different truncations and mutations (Fig. 2a).
When the vectors were expressed in the human monocytic cell
line THP-1, we observed that their basal expression broadly fell
into two groups (Fig. 2b). On the one hand, the reporters con-
taining the long 3-UTR isoform, only the distal 3-UTR half or
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Figure1. ThehumanNLRP33-UTR is alternativelypolyadenylatedand the isoformsaredifferentially expressed.a, thehumanNLRP33-UTR visualized
in the UCSC genome browser (hg19) with ESTs, polyadenylation sites from PolyA_DB, and mammalian conservation tracks. Location of AU-rich elements
(AUUUApentamers) are indicated.b, 3-RACEof theNLRP3 3-UTR in CD14monocytes orM-CSF-differentiatedmacrophages. PCRproductswere analyzedby
agarose gel electrophoresis. c–e, expression of the short and long 3-UTRwere quantified in theUCSCgenomebrowser for expression tracks sourced from the
ENCODE consortium (CSHL) (c), NIH Roadmap Epigenomics project (d), or GTEx project (e). The ratio for individual samples is plotted. f, qPCR analysis of 3-UTR
isoform expression in primary CD14monocytes or M-CSF-differentiated macrophages using primer pairs that amplify specifically within the short or long
3-UTR isoforms. Isoform expression was normalized to ACTB and expression of representative samples relative to the short isoform is shown.
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the ARE only, all of which contain the ARE, showed relatively
low expression (Fig. 2b, filled circles). On the other hand,
reporters containing the short 3-UTR isoform or the long
3-UTR with a mutated or deleted ARE, all of which lack a
functional ARE, were expressed at a higher level (Fig. 2b, open
circles). This was particularly obvious when the reporters were
grouped by presence of the ARE, where ARE-containing
reporters showed a significantly lower expression (Fig. 2c).
Because AREs are known to destabilize mRNAs (21), we also
measured mRNA stability of NLRP3 in THP-1 cells. We found
that NLRP3 was basally unstable with a half-life of 1.5 h and
that it could be stabilized after stimulating the cells with PMA
(Fig. 2d). Interestingly, when the samples were amplified by
3-RACE, the long 3-UTR isoform appeared to be especially
susceptible to degradation. This would be in agreement with
the location of the repressive ARE specifically in the long
3-UTR isoform (Fig. 2e).
TTP targets the ARE in the NLRP3 3-UTR
We next further analyzed the 3-UTR of the NLRP3 gene by
first screening for RNA-binding proteins that might impact its
expression. For this, we used an expression library of 58CCCH-
type zinc finger proteins (ZFPs) that has been used by Lacey et
al. (22) to identify novel regulators of TNF expression. We
co-expressed each ZFP expression vector with a luciferase
reporter containing the NLRP3 3-UTR or an empty vector
control. Expression of most ZFPs did not alter reporter expres-
sion, indicated by a relative expression around 1 (Fig. 3a and
supplemental Fig. S3). Expression of some ZFPs, including
threemembers of theMusclebind-like (MBNL) family, led to an
increase of relative reporter expression, indicating they might
be positive regulators of NLRP3 expression. Interestingly, a sin-
gle ZFP, Zfp36 (encoding Tristetraprolin/TTP), potently
repressed expression of the 3-UTR reporter (Fig. 3a and sup-
plemental Fig. S3). Given that TTP is a well known ARE-bind-
ing protein that generally represses target mRNAs (23), we
decided to test whether TTP could also target theNLRP3ARE.
To validate the result from the screen and to narrow down the
region targeted by TTP, we expressed the luciferase constructs
containing truncated regions of the NLRP3 3-UTRwith either
wild-type (wt) or a mutant of TTP, in which both zinc finger
motifs are disrupted (24). Similar to the result of the screen,
wild-type TTP was able to repress expression of the reporter
containing the full-length 3-UTR (Fig. 3b). Interestingly, it did
not affect expression of the short 3-UTR isoform, but strongly
repressed both the distal 3-UTR half, which contains the ARE,
as well as a reporter containing only the ARE (Fig. 3b). A
reporter containing a mutated ARE was also still repressed,
probably due to targeting of the smaller second ARE. As a neg-
ative control, expression of theGAPDH 3-UTRwas unaffected
by TTP overexpression (Fig. 3b). Importantly, overexpression
of mutant TTP did not repress expression of any reporter, indi-
cating that the effects of wild-type TTP are mediated by RNA
binding (Fig. 3b). For the long 3-UTR and ARE-only reporters,
mutant TTP even increased expression (Fig. 3b). This could be
due to dominant-negative effects of the mutant protein, which
can still bind proteins of themRNAdegradationmachinery but
not direct them to the target mRNA. We next wanted to con-
firm that TTP could also bind to the endogenous NLRP3
mRNA and used RNA immunoprecipitation to test this. In a
TTP pulldown, specifically the long NLRP3 3-UTR isoform
was enriched, similar to the IL1BmRNA,which is a knownTTP
target (25) (Fig. 3c). The specificity of the interaction was also
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confirmed by 3-RACE of the RNA-IP samples, which prefer-
entially amplified the long 3-UTR isoform in TTP pulldown
samples compared with IgG controls (Fig. 3d). Taken together,
these results suggest that TTP can bind to AREs specifically in
the long isoform of the NLRP3 3-UTR and repress its expres-
sion. This is also in agreement with results from two recent
reports that measured transcriptome-wide TTP association in
mousemacrophages (26, 27). In both studies, TTPwas found to
interact with ARE sequences in the distal part of the mouse
3-UTR.
TTP represses expression of endogenous humanNLRP3
We next aimed to test if TTP can also regulate endogenous
NLRP3 expression. To this end we knocked down TTP expres-
sion in THP-1 cells and primarymacrophages using siRNA and
assayed NLRP3 expression in response to PMA or LPS stimu-
lation, respectively. In both cases, TTP expression was effi-
ciently reduced by siRNA transfection (Fig. 4, a and c). Impor-
tantly, expression of the known TTP targets TNF (23) and
IL-1 (25) was increased in cells lacking TTP expression. Both
in THP-1 and macrophages, PMA- or LPS-induced Pro-IL-1
protein expression was increased (Fig. 4, a and c) and there was
also a trend to higher TNF and IL1BmRNA expression (Fig. 4,
b and d). In THP-1 cells, knockdown of TTP with two different
siRNAs led to an increase in PMA-induced NLRP3 protein
expression (Fig. 4a). Similarly, LPS-induced NLRP3 expression
was enhanced in primary macrophages that were transfected
with a TTP-specific siRNA (Fig. 4c). There was also a trend to
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increased NLRP3 mRNA expression upon TTP knockdown in
macrophages (Fig. 4d). In THP-1 cells, however, mRNA levels
were unchanged by TTP knockdown (Fig. 4b), suggesting that
TTP primarily affected translation of NLRP3 in these cells.
TTP represses NLRP3 inflammasome activation
Because TTP knockdown increased NLRP3 expression, we
next tested if it could affect NLRP3 inflammasome activation.
As we had seen before, TTP knockdown led to an increase in
LPS-induced expression of NLRP3 and Pro-IL-1 in primary
macrophages (Fig. 5a and supplemental Fig. S4a). Similarly,
TTP knockdown increased NLRP3 expression in THP-1 cells
(supplemental Fig. S4b). As expected, activation of the NLRP3
inflammasome in primed cells using nigericin led to the cleav-
age of Caspase-1 and its release into the supernatant (Fig. 5a
and supplemental Fig. S4). In human macrophages, cleaved
IL-1was also released upon nigericin stimulation (Fig. 5a and
supplemental Fig. S4a). Importantly, all of these readouts were
increased in cells transfected with two different TTP-specific
siRNA (Fig. 5a and supplemental Fig. S4). Pyroptotic cell death
induced by nigericin treatment of LPS-primed macrophages as
measured by LDH release was also increased upon TTP knock-
down (Fig. 5b). In accordance with increased inflammasome
activation, release of IL-1 and IL-18, as measured by ELISA,
was higher in cells transfected with two different TTP siRNA
(Fig. 5c). Similarly, the LPS-induced release of the known TTP
target TNF was increased in TTP knockdown cells (Fig. 5c).
To test the specificity of TTP in regulating other inflam-
masomes, we also activated the AIM2 and NLRC4 inflam-
masome by poly(dA:dT) transfection (28, 29) and Salmonella
typhimurium infection (30, 31), respectively. Activation of
NLRP3, AIM2, or NLRC4 inflammasome in LPS-primed
macrophages led to the cleavage and release of IL-1 and
Caspase-1 (Fig. 6a). Although both were increased in TTP
knockdown cells stimulated with nigericin, only IL-1 release
was increased in cells transfected with poly(dA:dT) or infected
with Salmonella, probably due to increased expression of Pro-
IL-1 (Fig. 6a). This wasmirrored by an increased release of the
direct TTP targets IL-1 and TNF in TTP knockdown cells
regardless of which inflammasome was activated (Fig. 6, b and
c). However, release of IL-18 was only increased in TTP knock-
down cells after NLRP3 activation, with little or no increase
following AIM2 or NLRC4 activation (Fig. 6c). Of note, inflam-
masome activation by Salmonellawasmuch stronger than after
stimulation with nigericin or poly(dA:dT), resulting in very
high release of IL-1, IL-18, and cleavedCaspase-1 (Fig. 6, a–c).
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Cell death resulting from strong inflammasome activation is
also likely to be responsible for the low expression of proteins in
the cell lysate of Salmonella-infected samples (Fig. 6a). Even
though Salmonella infection can also activate NLRP3 (32), the
lack of difference in Caspase-1 activation and IL-18 release
indicates that the contribution of NLRP3 in our protocol is
negligible, possibly due to the relatively short incubation time.
Overall, our findings suggest that TTP can repress NLRP3
inflammasome activity but does not affect AIM2 or NLRC4.
At the same time, TTP directly targets IL-1 and TNF
and represses them irrespective of which inflammasome is
activated.
Discussion
In this study, we report a detailed analysis of the NLRP3
3-UTR and identify TTP as a novel inducible regulator of
NLRP3 expression. We found that human NLRP3 can be alter-
natively polyadenylated, resulting in transcripts containing a
long or short 3-UTR isoform. The isoforms can, furthermore,
be differentially expressed in different cell types and tissues. In
recent years, alternative polyadenylation has emerged as an
important mechanism of gene expression regulation. Alterna-
tive 3-UTR isoform selection has been shown to generate tis-
sue-specific gene expression (33), but also to contribute to acti-
vation (34, 35) and malignant transformation of cells (36, 37).
More recently, it has even been linked to alternative protein
localization depending on which 3-UTR isoform the encoding
transcript contained (38). In the case of NLRP3, the short iso-
formcould contribute to higher gene expression, due to the lack
of both TTP and miR-223 regulation. For example, transcripts
containing the short isoform could provide basal NLRP3
expression, whereas the long 3-UTR could contribute more to
its inducible expression or differential expression between cell
types.
We also demonstrate that the RNA-binding protein TTP can
bind to and repress specifically the long 3-UTR isoform, most
likely by binding to a main AU-rich element and possibly more
weakly to a shorter ARE. TTP can also repress endogenous
NLRP3 expression, since siRNA-mediatedTTP knockdown led
to increased NLRP3 expression in PMA-stimulated THP-1
cells and LPS-stimulated primary human macrophages. Espe-
cially in THP-1 cells, there was little effect on NLRP3 mRNA
levels, whereas NLRP3 protein expression was increased. This
points to a reduction of translation efficiency in the presence of
TTP, which is increasingly recognized as an important feature
of TTP-mediated repression (39, 40). Finally, we show that
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inhibition of NLRP3 expression by TTP is also functionally rel-
evant, since NLRP3 inflammasome activation was exacerbated
in TTP knockdown cells, indicated by increased Caspase-1 and
IL-1 cleavage, IL-18 release, and cell death. Like Caspase-1
cleavage, increased IL-18 production is likely to be a direct con-
sequence of increased inflammasome activation, since the IL18
3-UTR does not contain any AU-rich elements and can there-
fore not be directly targeted by TTP. At the same time, TTP
knockdown had little effect on the activation of the AIM2 and
NLRC4 inflammasome, suggesting that NLRP3 is targeted spe-
cifically. Overall, these findings point to an important role of
TTP as a feedback regulator during the priming phase of
the NLRP3 inflammasome activation. Importantly, TTP can
repress both NLRP3 and Pro-IL-1, which is a known TTP
target (25), and therefore has a combinatorial inhibitory effect.
The role of TTP as a regulator of the inflammatory response
has been intensively studied due to the dramatic inflammatory
phenotype of TTP-deficient mice, which spontaneously de-
velop cachexia, dermatitis, and erosive polyarthritis (41).
This has been linked to overproduction of the TTP target
TNF, since treatment with TNF neutralizing antibodies (42)
or crossing mice to a TNF receptor 1 (Tnfr1)-deficient back-
ground (43), rescued most of the TTP knock-out phenotypes.
However, the same is true for genetic ablation of the IL-23/-17
axis, suggesting that awider cytokine network, probably includ-
ing feedback loops with TNF, is responsible for the phenotype
of Zfp36/ mice (44). Indeed, many cytokines and chemo-
kines other than TNF have been shown to be direct targets of
TTP, including IL-10, IL-1, IL-3, IL-6, CXCL1, CCL3, and
GM-CSF (45). Given our findings, overactivation of the NLRP3
inflammasome could be another contributing factor to the
global inflammation in these mice. Indeed, high levels of circu-
lating IL-1 have been reported in Zfp36/mice (46, 47).
The regulation of TTP, in particular its close connection to
p38 MAPK signaling, has been studied extensively. Upon LPS
stimulation of macrophages, p38 signaling leads to the phos-
phorylation of TTP by the downstream kinaseMK2 (48), which
impacts activity and expression of TTP in a number of ways
(reviewed in Ref. 49). An important effect of TTP phosphory-
lation is the inhibition of its ability to degrade target mRNAs,
probably due to the interaction with 14-3-3 proteins, which
interferes with the recruitment of the deadenylases CCR4 and
CAF1 (50, 51). This also directly affects TTP expression,
because TTP is involved in a negative feedback loop by target-
ing AREs in its own 3-UTR (52, 53). Thus, phosphorylation of
TTP increases itsmRNA stability and expression. Finally, phos-
phorylation also increases TTP protein stability by protecting it
from proteasomal degradation (54). The overall effect of this is
rapid accumulation of TTP. Because this pool of TTP is largely
phosphorylated and therefore inactive, TTP target mRNAs are
relatively stable at this stage. However, prolonged LPS stimula-
tion leads to the induction of yet another negative feedback
regulator, the phosphatase DUSP1 (also known as MKP-1).
DUSP1 inhibits p38 signaling (55), which allows TTP to be de-
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phosphorylated by PP2A (56). This ultimately reactivates the
accumulated pool of TTP and leads to the rapid degradation of
target mRNAs. Targeting the phosphorylation state of TTP is
an interesting prospect to modulate the severity of inflamma-
tory conditions, such as experimental arthritis (57). The timing
of TTP phosphorylation, occurring between 3 and 6 h post-
stimulation, is strikingly similar to the priming phase in typical
NLRP3 activation protocols. It is therefore tempting to specu-
late that phosphorylation of TTP could contribute to NLRP3
induction during priming due to temporal NLRP3 mRNA sta-
bilization and/or translational derepression. Interestingly, p38
has been shown to be required for the induction of NLRP3 by
LPS (58). At the same time, prolonged LPS stimulation could
hinder inflammasome activation because of TTP reactivation.
Chronic LPS stimulation has indeed been linked to decreased
NLRP3 expression and inflammasome activation (59, 60).
Repression of NLRP3 by prolonged LPS stimulation has also
been connected to IL-10 induction, which can inhibit NLRP3
expression (59). This provides another possible link to TTP,
since IL-10 is a potent inducer of TTP expression and TTP is
needed for the full anti-inflammatory effects of IL-10 (61, 62).
IL-10 has been found to repress NLRP3 expression in the
inflamed joints in a mouse model of arthritis (63) and colonic
macrophages (64). Additionally, a regulatory T cell subset, Tr1
cells, can suppress NLRP3 priming in macrophages by produc-
ing high levels of IL-10 (65). Furthermore, increased expression
and activation of NLRP3 and inflammasome-dependent IL-1
production in IL-10 knock-out mice drive the development of
spontaneous colitis (66) and severity of antigen-induced arthri-
tis (63). The same is true for intestinal inflammation in IL-10R
knock-out mice or patients harboring a loss-of-function muta-
tion in the IL-10R (67). In colonic macrophages, the suppres-
sion of NLRP3 by IL-10 has been shown to happen at the post-
transcriptional level, because NLPR3 protein is repressed
without an effect on mRNA expression (64). The authors
hypothesize that this is due to increased protein degradation,
since treatment with the proteasome inhibitor MG132 in-
creases NLRP3 expression. However, it could also be an indi-
rect effect via TTP, because TTP expression is critically regu-
lated by proteasomal degradation (54). IL-10 might chronically
stimulate TTP expression in colonic macrophages, which
represses NLRP3 and Pro-IL-1 expression. Either IL-10 or
proteasome inhibition could then disrupt this regulatory loop
and restore inflammasome activation.
TTP andNLRP3have been shown to have opposing effects in
a number of diseases. For example, TTP deficiency has been
shown to exacerbate disease progression in theApoE/model
of atherosclerosis (47), whereas it is blunted inNLRP3-deficient
mice (9). TTP knock-out mice are also more susceptible to
DSS-induced colitis (68), which has been shown to involve acti-
vation of the NLRP3 inflammasome. Conflicting results have
been reported about the role of inflammasomes in DSS colitis,
with some reports finding that mice deficient in inflammasome
components are protected (69, 70), whereas others report the
opposite (71, 72). This is likely due to a complex cross-talk
between the different genotypes and the microbiome (73).
Given the pathogenic role of NLRP3 also in chronic models of
colitis (66, 67), inflammasome activation is likely to be a driver
of intestinal inflammation. Furthermore, TTP has been shown
to suppress the development of different models of arthritis.
For example, prevention of TTP phosphorylation in Zfp36aa/aa
mice or by treatment with a PP2A agonist can protect mice
from serum transfer-induced arthritis and zymosan-induced
inflammatory arthritis (57). Similarly, TTP overexpression in
Zfp36ARE mice is protective in collagen antibody-induced
arthritis (74). Notably, NLRP3 inflammasome activation and
IL-1 have been shown to be important drivers of arthritis in
A20-deficientmice (75), ANK-deficientmice (76), and antigen-
induced arthritis (63). In all examples mentioned above, TTP
could suppress chronic inflammation caused by NLRP3 ago-
nists in atherosclerotic plaques, arthritic joints, and the
inflamed intestines. Consequently, TTP deficiency could
worsen disease at least partially due to increased inflammasome
activation. Equally, boosting TTP expression or activity could
be beneficial by reducing NLRP3 activity among other anti-
inflammatory effects.
In conclusion, we have identified TTP as a negative regulator
of NLRP3, which could be particularly important during
inflammasome priming and might contribute to IL-10-medi-
ated inflammasome repression. Because TTP also represses
IL-1 expression, it is a dual inhibitor of the IL-1 system.
TTP-mediated reduction of the NLRP3 inflammasome activa-
tion could also reduce the development of chronic inflamma-
tory diseases, such as atherosclerosis, colitis, and arthritis. We
also found that human NLRP3 can be alternatively polyadeny-
lated, which enables yet another level of regulation. Switching
to predominant expression of the short 3-UTR isoform could
relieve repression not only by TTP but alsomiR-223. Targeting
by TTP and alternative polyadenylation could help to explain
how NLRP3 expression is regulated in macrophages and other
cell types and during disease. TTP or the modulation of TTP
activity via p38 signaling or PP2A might also provide new tar-
gets for therapeutic intervention in NLRP3-driven diseases.
Experimental procedures
Cell culture
THP-1, PBMCs, and primary human macrophages were
maintained in RPMI 1640 medium and HEK293T were main-
tained in DMEM (Gibco), both with GlutaMAX-I and supple-
mented with 10% FCS and 1% (v/v) penicillin/streptomycin
solution (both from Sigma). PBMCs were isolated from whole
blood or buffy coats (supplied by the Irish Blood transfusion
service) of healthy donors using Lymphoprep (Stemcell Tech-
nologies) density gradient medium. Primary monocytes were
isolated from PBMCs by positive selection using anti-CD14
magnetic beads (Miltenyi Biotec) and the MACS system. Cells
were then differentiated into macrophages by cultivation with
50 ng/ml of recombinant human M-CSF (Immunotools) for 7
days. Murine bone marrow-derived macrophages were gener-
ated by incubating bone marrow cells of wild-type mice with
10% L929 cell supernatant as a source of M-CSF for 7 days.
THP-1 cells were activated with 12.5 ng/ml of PMA for the
indicated times. Primary humanmacrophages were stimulated
with 10 ng/ml of LPS as indicated. For inflammasome activa-
tion, THP-1 cells were primed with PMA (Sigma) for 8 h and
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primary human macrophages were primed with ultrapure
rough LPS (from Escherichia coli, serotype EH100; Alexis) for 2
(AIM2) or 3 h (NLRP3 or NLRC4). For NLRP3 activation, cells
were treatedwith 10Mnigericin (Invivogen) for 1 h.AIM2was
activated by transfection of 1g/ml of poly(dA:dT) (Invivogen)
with Lipofectamine 2000 (Invitrogen) for 6 h. For NLRC4 stim-
ulation, LPS-primed macrophages were grown in antibiotic-
free media and infected with S. typhimurium (UK-1) (multi-
plicity of infection 20). Cells were centrifuged at 300  g for 5
min and the media changed after 30 min to complete media
containing 100g/ml of Gentamycin (Sigma) to kill extracellu-
lar bacteria. Samples were analyzed after 1 h. For analysis of
cleaved Caspase-1 or IL-1 in the supernatant byWestern blot,
inflammasome activation was performed in serum-free media
as not to overload the precipitation step with serum proteins.
Transfection
Plasmid transfection ofHEK293T (2 105 cells/ml) for lucif-
erase assays was performed with GeneJuice (Novagen) or Lipo-
fectamine 2000 (Invitrogen) in complete media according to
the manufacturer’s instructions. For psiCHECK-2 vectors, 40
ng were transfected per well of a 96-well plate using GeneJuice.
If co-expressed with TTP expression vectors, 30 ng of psi-
CHK-2 plus 120 ng of expression vector were transfected. For
the ZFP screen, cells were transfected with 150 ng of ZFP
expression plasmid, 40 ng of pSGG (empty vector or NLRP3
3-UTR), and 10 ng of TK-Renilla per well using Lipofectamine
2000. THP-1 cells were batch transfected with plasmid DNA
using Lipofectamine 2000 (Invitrogen) according to manufa-
cturer’s instructions. In short, 3 106 cells in 3ml of antibiotic-
freemedia were transfected with 2.25g of DNA and 5.63l of
Lipofectamine and media changed to complete media 4 h after
transfection to minimize toxicity and then distributed to indi-
vidual wells.
Cells were transfected with siRNA using Viromer Blue
(Lipocalyx) according to the manufacturer’s instructions.
THP-1 cells were transfected with 40 nM and primary macro-
phages with 50 nM siRNA. Cells were generally used for assays
24 h post-transfection. siTTP_1 was as described before (77).
siScr_1 and siTTP_1 were synthezised by Eurofins Genomics,
siScr_2 (negative control No. 1) and siTTP_2 (s14979) were
Silencer Select from Ambion. siRNA sequences were: siScr_1
(UUCUCCGAACGUGUCACGUdTdT), siTTP_1 (CGAC-
GAUAUAAUUAUUAUAdTdT), and siTTP_2 (CUUUAUU-
UAUGACGACUUUdTdT).
Luciferase assay
Cells were lysed in 50l of 1 Passive lysis buffer (Promega)
48 h after transfection. 20 l of lysate was combined with 40 l
of Firefly or Renilla luciferase substrate and luminescence was
measured using a FLUOStar Optima (BMGLabtech). The sub-
strate solution for measuring Firefly luciferase activity was
Firefly luciferase assay mixture (10 mM Tricine, 0.535 mM
(MgCO3)4Mg(OH)25H2O, 1.335 mM MgSO47H2O, 0.05 M
EDTA, 16.65 mM DTT, 135 mM acetyl-Coenzyme A, 235 mM
D-luciferin, 265 mM ATP) and for Renilla luciferase activity
Coelenterazine (1 mg/ml diluted 1:1000 in PBS; Biotium) was
added. For each well, luciferase activity was normalized to the
internal control (Switchgear plasmids: Firefly reading divided
by Renilla reading; psiCHECK-2: Renilla reading divided by
Firefly reading). For the ZFP screen, sampleswith too low inter-
nal Renilla readings were excluded from the analysis.
Western blot
Cells were lysed in 2 Laemmli sample buffer and separated
by SDS-PAGE and blotted according to standard protocols. For
measurement of cleaved IL-1 and Caspase-1 in the superna-
tant, proteins in the supernatant were precipitated with 1%
(v/v) Strataclean Resin (Agilent Technologies) and beads lysed
in 2 sample buffer. Proteins were visualized using the HRP
substrateWesternBright Spray ECL (Advansta) on aChemiDoc
imaging system (Bio-Rad). Primary antibodies were: NLRP3
(Cell Signaling D2P5E, 1:1000), TTP (Millipore ABE285,
1:1000), -actin (Sigma AC-74, 1:15000), IL-1 (Pro and
cleaved) (R&D Systems AF-401, 1:1000), Caspase-1 p20
(Asp297) (Cell Signaling D57A2, 1:1000), and Pro-Caspase-1
p45 (A-19, Santa Cruz sc-622; 1:2000). HRP-conjugated sec-
ondary antibodies were from Jackson ImmunoResearch.
ELISA
Supernatants were collected and cytokine abundance deter-
mined by human IL-1 DuoSet ELISA (R&D Systems DY201),
human Total IL-18 DuoSet ELISA (R&D Systems DY318) or
humanTNF (Immunotools) ELISAkits according to theman-
ufacturer’s instructions.
Cell deathmeasurement
Supernatants were collected and cleared of cells by centrifu-
gation. LDH activity as a measure of lytic cell death was deter-
mined using the CytoTox 96 Non-Radioactive Cytotoxicity
Assay (Promega).
qPCR
RNA was isolated using the PureLink RNA Mini kit
(Ambion) or the RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. For measurement of NLRP3
3-UTR isoforms by qPCR, RNA was DNase-treated using the
TURBODNA-free kit (Ambion). RNAwas converted to cDNA
using the High Capacity cDNA reverse transcription kit
(Applied Biosystems) in duplicate, using a 1:1 mixture of ran-
dom primers and an anchored oligo(dT) primer (TTTTTT-
TTTTTTTTTTTTVN, synthesized by Eurofins Genomics).
cDNAwas then diluted 1:2–1:5 and one qPCR per reverse tran-
scription replicate assembled.Gene expressionwas determined
by SYBRGreen qPCR using the KAPA SYBR Fast qPCRMaster
Mix (KAPA Biosystems) or PowerUp SYBR Green Master Mix
(Applied Biosystems) on a 7500 Fast thermocycler (Applied
Biosystems). Oligonucleotide primers (Table 1) were designed
using PrimerQuest (IDT Technologies) and synthesized by
Eurofins Genomics as salt-free oligos. Primers were tested for
the presence of a single PCR product and acceptable amplifica-
tion efficiency. Relative expression was determined by Ct
calculation for one internal control gene. If more than one
internal control was used, the geometric mean of all controls
was used for normalization.
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3-RACE (rapid amplification of cDNA ends)
To amplify 3-UTR sequences ofNLRP3, RNA was first con-
verted to cDNA using polyT_T7 (CAGTGAATTGTAATAC-
GACTCACTATAGGTTTTTTTTTTTTTTTTVN) instead of
random primers/oligo(dT). 3-UTR sequences were amplified
by end point PCR (22–35 cycles) using the KAPA2G Fast
ReadyMix PCR kit (KAPA Biosystems) in 10-l reactions with
the common reverse primer T7_rev (CAGTGAATTGTA-
ATACGACTCACTATAGG) and gene-specific forward prim-
ers (hNLRP3_CDS_f, TGACCGTCGTCTTTGAGCCTTCTT;
hACTB_CSF_f, TCCACGAAACTACCTTCAACTC; mNlrp3_
CDS_f, CCTTAGAAGCGCTCCAGGAAGAAA). PCR prod-
uctswere separated on an agarose gel and bandswere visualized
with Nancy-520 (Sigma) on a gel imaging system (UVP) and
quantified using ImageJ.
Quantification of 3-UTR isoforms from sequencing data
Expression tracks from the Encyclopedia of DNA Elements
(ENCODE) (78), the NIH Roadmap Epigenomics project (79),
or theGene-Tissue Expression (GTEx) (80) projectwere loaded
into the Genome browser (GRCh37/hg19) using the respective
Track Hubs (81). The ENCODE data used in this article (ac-
cession numbers GSM758559, GSM758566, GSM981256,
GSM984609, GSM981257, GSM984606, and GSM984604)
were generated by the Gingeras lab (Cold Spring Harbor Labo-
ratory, Cold Spring Harbor, NY). The Roadmap Epigenomics
data used in this article was sourced from the Epigenome
Browser or the Roadmap Epigenomics Integrative Analysis
Hub. 30 random spleen samples and 56 random whole blood
samples were chosen from the GTEx RNA-seq Signal
hub. Windows for the short (Window 1: chr1:247,611,808-
247,612,121) and long NLRP3 3-UTR isoform (Window 2:
chr1:247,612,120-247,612,407) were defined. For all tracks, the
average value of both windows was recorded from the details
page. Expression of the short isoform was estimated by sub-
tracting the average value of Window 1 from the average value
of Window 2. Expression of the long isoform was estimated as
the average value of Window 2. The ratio of short to long iso-
form expression was plotted for each track.
mRNA stability measurement
THP-1 cells were first treated with PMA as indicated and
then 2 g/ml of Actinomycin D was added to stop transcrip-
tion. Cells were lysed for RNA analysis at the indicated times
after Actinomycin D addition.
Plasmids
NLRP3 3-UTR and control firefly luciferase reporter vector
(Switchgear Genomics) and TK-Renilla (Promega) used for the
ZFP screen have been described previously (15). ZFP expres-
sion vectors have been described previously (22) and were
kindly provided by Dr. Derek Lacey and Dr. Marco Herold
(WEHI, Melbourne). Expression vectors for murine wild-type
and ZFP mutant (m1,2) TTP have been described previously
(82) and were kindly provided by Prof. Georg Stoecklin (Uni-
versity of Heidelberg).
3-UTR sequences were cloned into the psiCHECK-2 (Pro-
mega) empty vector using a nested PCR setup using the KAPA
HiFi Hotstart ReadyMix (Kapa Biosystems) PCR kit. In the first
PCR step, genomic 3-UTR regions were amplified for 15 cycles
with 60 °C annealing temperature with genomic DNA (human:
Promega Human Genomic DNA) as input. The following
primer pairswere used: humanNLRP3 (forward, TATCTGAA-
GAGTGCAACCCAGGCT; reverse, ACTCTCAAACCTTTC-
CCTCCACGA); and human GAPDH (forward, CATGGC-
CTCCAAGGAGTAAG; reverse, CCAGCAAGAATGTCT-
CACCT). Next, the 3-UTRs were further amplified using the
primary PCR as input for 3 cycles with 55 °C and 23–27 cycles
60 °C annealing temperature. The primer pairs containing
restriction sites were: NLRP3long (ctgacgctcgagaGAGTG-
GAAACGGGGCTGCCAGA, cgcatggcggccgcgTTTTTTA-
AAATTAAGAAAAGGA); NLRP3short (ctgacgctcgaga-
GAGTGGAAACGGGGCTGCCAGA, cgcatggcggccgcg-
AAAATAAAGAAAGTGCTTTATT); NLRP3end (ctgacg-
ctcgagaGATCTCTTCTCTGTCTAACTTT, cgcatggcggccgcg-
TTTTTTAAAATTAAGAAAAGGA); NLRP3ARE (ctgacgct-
cgagaTTGACTATATATTATGTTGAAAT, cgcatggcggccgcg-
TTTTCTTATTAGAAAACAAAACT); GAPDH3 (ctgacg-
ctcgagACCCCTGGACCACCAGCCCC, gcgtgggcggccgc-
TGGTTGAGCACAGGGTACTT).
PCR products were separated by agarose gel electrophoresis
and bands of the correct size were gel purified using theWizard
SV Gel and PCR Clean-Up System (Promega). Gel-purified
inserts and 5 g of vector DNA were digested with XhoI and
NotI (New Engalnd Biolabs). Digested vectors were dephos-
phorylated by adding 1 l of CIP (New England Biolabs) into
the digestion reaction. Digested vectors and inserts were gel-
purified and ligated overnight at 4 °C usingT4DNA ligase (Pro-
mega), transformed into competent bacteria, and selected on
LB-Amp plates. Vectors were sequenced using the sequencing
primer GTGCTGAAGAACGAGCAGTA.
NLRP3AREdel and NLRP3AREmut were generated from
psiCHK2-NLRP3long by site-directed mutagenesis using the
QuikChange Lightning kit (Agilent Technologies) according
to manufacturer’s instructions. Mutagenesis primers were
designed with the QuikChange Primer Design tool and were:
AREdel (forward, gactatatattatgttgaaattttatggcagctaattttt-
tgtaacagttttgttttctaataaga; reverse, tcttattagaaaacaaaactgtt-
acaaaaaattagctgccataaaatttcaacataatatatagtc) and AREmut (for-
ward, ttgaaattttatggcagctatCtatCtatCtaaattttttgtaacagttt;
reverse, aaactgttacaaaaaatttaGataGataGatagctgccataaaat-
ttcaa).
Table 1
Primers for SYBR Green qPCR
qPCR Forward Reverse
hACTB CACAGAGCCTCGCCTTT GAGCGCGGCGATATCAT
hGAPDH AGCCGAGCCACATCGCT GCAACAATATCCACTTTACCAGAGT
hIL1B AGCTGATGGCCCTAAAC
AGA
TGTCCATGGCCACAACAACTGA
hNLRP3 TGGATCTTCGCTGCGAT
CAACA
TCAATGCTGTCTTCCTGGCA
hNLRP3long TCTCTTCTCTGTCTAAC
TTTCTT
GCGGGAATGATGATATGAGCAAA
hNLRP3short ATGCCTTCCTGTGCAGA
GCTT
AGGCGCTGTGATGACAACAA
hRPS13 CGAAAGCATCTTGAGAG
GAACA
TCGAGCCAAACGGTGAATC
hTNF CCAGGGACCTCTCTCTA
ATCA
TCAGCTTGAGGGTTTGCTAC
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RNA immunoprecipitation
Per sample, 1–2  107 THP-1 cells were treated with PMA
for 4 h and then lysed for 10 min on ice in RIP buffer (1% (v/v)
Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1 mM
MgCl2, 10% (v/v) glycerol, 1 mM DTT, supplemented with 50
mM NaF, 1 Na3VO4, 1 mM PMSF, 1 g/ml of leupeptin, 0.5%
(v/v) aprotinin (5–10 TUI/ml)). The lysate was cleared from
nuclei by centrifugation for 5min at 2000 g at 4 °C. The lysate
was then precleared for 30 min at 4 °C with 5% (v/v) equili-
brated protein A/G PLUS-agarose beads (Santa Cruz). Beads
were removed by centrifugation and an aliquot of the lysate
taken as the input sample. The rest of the lysate was then incu-
bated with 2 g of anti-TTP (ABE285) or rabbit IgG control
antibody (both Millipore) for 1.5 h at 4 °C. 5% (v/v) washed
protein A/G beads were added for another 1.5 h. The beads
were washed 5 times in RIP buffer and pulldown and input
samples lysed inQiazol (Qiagen). RNAwas extracted according
to themanufacturer’s instructions, with the addition of 15g of
linear polyacrylamide (prepared according to Delaney lab pro-
tocol (University of Vermont)) to the aqueous phase prior to
RNA precipitation with isopropyl alcohol. Equal volumes of
RNA were then converted to cDNA and relative target mRNA
enrichment was determined by qPCR.
Statistics
p values were calculated by two-sided Student’s t test (not
assuming equal variance) inGraphPad Prism. Linear regression
analysis of RNA stabilitymeasurements was also done in Prism.
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